http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_06defff03cadbd85aee462f5570a4ce1
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Abrams |
| name | Jeffrey S. Abrams Jeffrey S Abrams |
| given-name | Jeffrey S Jeffrey S. |
| organization-name | University Medical Center at Princeton, Princeton, New Jersey 17Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland. 7Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Cancer Therapy and Evaluation Program, National Cancer Institute, Bethesda, MD Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Edward L. Korn, Boris Freidlin, and Jeffrey S. Abrams, National Cancer Institute, Bethesda, MD; and Susan Halabi, Duke University Medical Center, Durham, NC. Princeton Orthopaedic and Rehabilitation Associates, and University Medical Center at Princeton, Princeton, New Jersey, USA. Cancer Therapy Evaluation Program, Division of Cancer Therapy and Diagnosis, National Cancer Institute, Rockville, Maryland Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland 20892, USA. Princeton Orthopaedic and Rehabilitation Associates, NJ Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA National Cancer Institute, Bethesda, MD Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA Department of Orthopedics Surgery, Seton Hall University, School of Medical Education, Orange, NJ, USA. Edward L. Korn and Boris Freidlin, Biometric Research Branch; and Jeffrey S. Abrams, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD. From the Biometric Research Branch and Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD All authors: National Cancer Institute, Bethesda, MD. Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda, MD, USA From the Massachusetts General Hospital Cancer Center, Boston, MA; Mayo Clinic, Rochester, MN; Angeles Clinic and Research Institute, Los Angeles, CA; Inova Fairfax Hospital, Falls Church, VA; University of Vermont, Burlington, VT; Institut Jules Bordet, Brussels, Belgium; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; National Cancer Institute of Canada, Clinical Trials Group, Kingston, Ontario, Canada; Toronto Sunnybrook Odette Cancer Centre, University of Toronto,... Cancer Therapy Evaluation Program Division of Cancer, Treatment and Diagnosis National Cancer Institute Bethesda, MD, USA From the National Cancer Institute, Bethesda, MD; University of Massachusetts, Worcester, MA; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Institut National du Cancer, Paris, France; Latin American and Caribbean Society of Medical Oncology, Buenos Aires, Argentina; European Organisation for Research and Treatment of Cancer, Brussels; GlaxoSmithKline Biologicals, Rixensart, Belgium; Medical Research Council Clinical Trials Unit, London; National Cancer Research... National Cancer Institute, Bethesda, MD, USA. Department of Surgery, University Medical at Princeton, Princeton, NJ, USA. From Genentech, South San Francisco, CA; Eli Lilly, Indianapolis, IN; GlaxoSmithKline, Philadelphia, PA; Novartis Pharma AG, Basel, Switzerland; Cancer and Leukemia Group B, Statistical Center, Duke University Medical Center, Durham, NC; American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and Cancer and Leukemia Group B, University of Chicago, Chicago, IL. Boris Freidlin, National Cancer Institute, Bethesda, MD; Edward L. Korn, National Cancer Institute, Bethesda, MD; and Jeffrey S. Abrams, National Cancer Institute, Bethesda, MD From Emory University, Atlanta, GA; National Cancer Institute; United BioSource Corporation, Bethesda; US Food and Drug Administration, Rockville, MD; University of Pennsylvania, Philadelphia, PA; University of California, Los Angeles, Los Angeles, CA; and Bayer Pharmaceuticals, Montville, NJ 1National Cancer Institute, Bethesda, Maryland. National Cancer Institute, USA. From the Biometric Research Branch, Clinical Investigations Branch, and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD. |
Incoming Links
Total number of triples: 122.